Ledipasvir/sofosbuvir: the fixed dose combination in the new era of treatment for HCV
DOI:
https://doi.org/10.7175/rhc.v6i3.1178Keywords:
Ledipasvir, Sofosbuvir, HCVAbstract
Interferon-based treatment is not suitable for many patients with hepatitis C virus (HCV) infection because of contraindications, other reasons for ineligibility and side-effects. The fixed dosed combination ledipasvir/sofosbuvir (LDV / SOF) is the first approved regimen that doesn’t require administration with interferon or ribavirin. LDV / SOF is also the first single-pill approved for the treatment of chronic HCV genotype 1 in both treatment-naïve and treatment-experienced patients. The results of the phase III studies demonstrate the combination has been very well tolerated and SVR rates consistently above 90%. Objective of this review is to present clinical evidence of efficacy and safety of the combination LDV / SOF in different subgroups of patients with HCV.
References
Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383: 515-23; http://dx.doi.org/10.1016/S0140-6736(13)62121-2
Sovaldi. Riassunto delle caratteristiche di prodotto
Harvoni. Riassunto delle caratteristiche di prodotto
U.S Food and Drug Administration. FDA approves first combination pill to treat hepatitis C. FDA News Release, ottobre, 2014. Disponibile su: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418365.htm (ultimo accesso marzo 2015)
European Medicine Agency. Harvoni recommended for the treatment of chronic hepatitis C. Press Release, 26/09/2014
Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014; 146: 736-43; http://dx.doi.org/10.1053/j.gastro.2013.11.007
Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98; http://dx.doi.org/10.1056/NEJMoa1402454
Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93; http://dx.doi.org/10.1056/NEJMoa1316366
Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88; http://dx.doi.org/10.1056/NEJMoa1402355
Bourlière M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir/sofosbuvir fixed-dosed combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy. 65th Annual Meeting of America Association for the Study of Liver Disease. Boston, 2014: Abstract LB-6
Bourlière M, Sulkowski M, Omata M, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. 65th Annual Meeting of America Association for the Study of Liver Disease. Boston, 2014: abstract 82
Flamm SL, Everson GT, Charlton MR, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. 65th Annual meeting of the American Association for the Study of Liver Diseases. Boston, 2014: abstract 239
Reddy KR, Everson GT, Flamm SL, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post-trasplant recurrence: preliminary results of a prospective, multicenter study. 65th Annual meeting of the American Association for the Study of Liver Diseases. Boston, 2014: Abstract 8
Osinusi A, Kohli A, Marti MM, et al. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med 2014; 161; 634-8; http://dx.doi.org/10.7326/M14-1211
Rockstroh JK, Puoti M, Rodriguez-Torres M, et al. Sofosbuvir and ribavirin therapy for the treatment of HIV/HICV coinfected patients with HCV G 1-4 infection: the PHOTON-1 and -2 trials. 65th Annual meeting of the American Association for the Study of Liver Diseases. Boston, 2014: Abstract 195
Naggie S, Cooper C, Saag M, et al. Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1: ION-4. The annual Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, 2015: abstract 152LB
Gane EJ, Hyland RH, Anet D, et al. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience. 49th Annual Meeting of the European Association for the Study of the Liver (EASL). Londra, 2016: abstract 06
Gane EJ, Hyland RH, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. 65th Annual meeting of the American Association for the Study of Liver Diseases. Boston, 2014: abstract LB-11
Kapoor R, Kohli A, Sidharthan S, et al. treatment of hepatitis C genotype 4 with ledipasvir and sofosbuvir for 12 weeks: results of the SYNERGY trial. 65th Annual meeting of the American Association for the Study of Liver Diseases. Boston, 2014: abstract 240
Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71; http://dx.doi.org/10.1002/hep.20119
Incivo. Riassunto delle caratteristiche di prodotto
Victrelis. Riassunto delle caratteristiche di prodotto
McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92; http://dx.doi.org/10.1056/NEJM199811193392101
Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32; http://dx.doi.org/10.1016/S0140-6736(98)07124-4
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65; http://dx.doi.org/10.1016/S0140-6736(01)06102-5
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82; http://dx.doi.org/10.1056/NEJMoa020047
Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55; http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00010
McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93; http://dx.doi.org/10.1056/NEJMoa0808010
Pegasys – Riassunto delle caratteristiche di prodotto
Pegintron – Riassunto delle caratteristiche di prodotto
Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection n treatment-naïve patients: results from QUEST-1, a phase III trial. 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam, 2013: abstract 1425
Manns M, Marcellin P, Poordad FP, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection n treatment-naïve patients: results from QUEST-2, a phase III trial. 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam, 2013: abstract 1413
Ferenci P, Asselah T, Foster GR, et al. Falaprevir plus pegylated interferon alfa2a and ribavirin in chronic HCV genotype-1 treatment-naïve patients: Final results from STARTVERSO1, a randomized, placebo-controlled phase III trial. 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam, 2013: abstract 1416
Fontaine H, Hezode C, Dorival C, et al. SVR12 rates and safety of triple therapy including Telaprevir or Boceprevir in 221 cirrhotic non-responders treated in the French early access program (ANRS CO20-CUPIC). 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam, 2013: abstract 60
Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87; http://dx.doi.org/10.1056/NEJMoa1214853
Lawitz E, Wyles D, Davis M, et al. Sofosbuvir + peginterferon + ribavirin for 12 weeks achieves 90% SVR12 in genotype 1, 4, 5, or 6 HCV infected patients: The NEUTRINO study. 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam, 2013: abstract 1411
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
